home
enabling drug discovery in the ubiquitin field since 2010
Access to well defined ubiquitinated peptides and conjugates, which could so far not be routinely produced (bio)chemically, is of paramount importance for screening assays for the identification of new drugs, as well as for fundamental research and structural studies. Since we founded our company in 2010, it is well recognised that our products enable research in the rapidly expanding ubiquitin field. Please find out about how our reagents expedite the three stages of early drug discovery; target - lead - lead on target:
target
Identify and validate your target using UbiQ Probes.
lead
Screen your compounds targeting DUBs and Ubl proteases using UbiQ Assay reagents.
lead on target
Our reagents enable you in lead on target validation and lead optimization.
target
Identify and validate your target using UbiQ Probes.
lead
Screen your compounds targeting DUBs and Ubl proteases using UbiQ Assay reagents.
lead on target
Our reagents enable you in lead on target validation and lead optimization.
reagents
UbiQ develops, manufactures and commercializes ubiquitinated peptides, ubiquitin-based reagents and high throughput assays in our own laboratory at the Amsterdam Science Park. Next to ubiquitin, we also make ubiquitin-like variants (SUMO, ISG15, NEDD8, etc) of our reagents. Important to note is that all our products are "For laboratory research use only, not for use in humans".
custom made reagents
With our UbiQ technologies we are able to fully synthesize site-selective ubiquitinated peptides of native conformation, using automated solid phase peptide synthesis. This enables us to synthesize any custom made peptides.
our blog
Reagents for your SARS-CoV-2 research
Reagents for your SARS-CoV-2 research The SARS-CoV-2 coronavirus encodes a papain-like cysteine protease PLpro (NSP3) that cleaves the viral polyprotein, removes ubiquitin-like ISG15 protein modifications and (with lower activity) Lys48-linked polyubiquitin chains. As PLPro is essential for SARS-CoV-2 replication, it represents a promising target for...
In memoriam: Professor Huib Ovaa
On the 19th of May 2020, our co-founder and dear friend Professor Dr. Huib Ovaa passed away from prostate cancer at the age of 46 years. In the past year, Huib has undergone a...
Public-private partnership grant by Health-Holland: New drug therapies by a better understanding of ubiquitin metalloprotease activity Tools to study ubiquitin metalloprotease activity.
17 December 2019 Public-private partnership grant awarded by Health-Holland We are happy to announce that UbiQ and Prof Titia Sixma (Netherlands Cancer Institute, Netherlands) were recently awarded a public-private partnership...
Antibody development by using monoubiquitinated peptides as antigens.
24 April 2019 Antibody development by using monoubiquitinated peptides as antigens Conserved from yeast to human, the histone methyltransferase Dot1 methylates lysine 79 of histone H3 (H3K79) on the nucleosome core. This methylation affects gene expression and DNA damage...
A collaborative effort between scientists at UbiQ, Genentech, Boston Biochem (Bio-Techne) and Stanford University.
28 January 2019 Bio-orthogonally tagged activity-based probes forproteomics of deubiquitinating enzymes A recent paper in Nature Communications describes a collaborative effort between scientists at UbiQ, Genentech, Boston Biochem (Bio-Techne) and Stanford University (1). Here a reactive-site-centric chemoproteomics protocol is presented...
where to meet us
EMBO conference on Ubiquitin 2022
September 9 - 13, 2022 Cavtat, Croatia Ubiquitin and ubiquitin-like proteins in health and disease. Contact: Alfred Nijkerk (CEO)
GRK2243 Symposium, University of Würzburg (cancelled by COVID19)
May 4 - 6, 2020 Würzburg, Germany Understanding Ubiquitylation: From Molecular Mechanisms to Disease Contact: Farid El Oualid (CSO) More info conference: https://www.ubiquitin-wuerzburg-2020.de/
recent publications
UBC9 and EME1 sumoylation foster ribosomal DNA damage repair in CPT response
UBC9 and EME1 sumoylation foster ribosomal DNA damage repair in CPT response Easa Nagamalleswari, Karishma Bakshi, Jan Breucker, Michaela Gschweitl, Román González-Prieto, Nathalie Eisenhardt, Chronis Fatouros, Viduth K Chaugule, Alfred C.O. Vertegaal, Andrea Pichler DOI: https://doi.org/10.1101/2022.04.11.487628
Collaborative research between the University of York, University of Glasgow and UbiQ looks into the (essential) roles of ubiquitin proteases (DUBs) and ubiquitin conjugation in Leishmania parasites.
21st Royal Society of Chemistry - Medicinal Chemistry Symposium, 13 - 15 September 2021, Cambridge UK. Poster title: A ubiquitin activating enzyme as a novel therapeutic target for leishmaniasis. Daniel Harris (1), Dr Mads Gabrielson (2),...
Anti–COVID-19 Drug Design by targeting a molecular scissor of Ubiquitin and ISG15.
UbiQ is proud to have been part of a major collaboration reported recently by Rut et al. in Science Advances, describing the activity profiling and crystal structures of inhibitor bound SARS-CoV-2 PLpro: Activity profiling and...
Leishmania differentiation requires ubiquitin conjugation mediated by a UBC2-UEV1 E2 complex.
Collaborative research between the University of York, University of Glasgow and UbiQ looks into the (essential) roles of ubiquitin proteases (DUBs) and ubiquitin conjugation in Leishmania parasites. Leishmaniasis is a neglected tropical disease caused by...
Strategy for Development of Site-Specific Ubiquitin Antibodies.
As part of collaborative research between The Netherlands Cancer Institute, Leiden University Medical Centre, UbiQ and the University of Amsterdam, van Kruijsbergen et al. report in Frontiers in Chemistry detailed protocols for the development...